Riskpilot← Back to searchSign inGet full accessNovadoc AB
ABActiveOrg 5590754031Toftavägen 25General medical practice activities · NACE 8621Est. 20161 employees
Revenue 2025
SEK 1,9M
-14% vs 2024
EBITDA margin
78.7%
+69% vs 2024
Equity ratio
81.2%
Financial strength
Net profit 2025
SEK 1,4M
+14% vs 2024
| Revenue | SEK 1,9M | -14% |
| EBITDA | SEK 1,5M | +69% |
| Net profit | SEK 1,4M | +14% |
| Total assets | SEK 5,3M | +14% |
| Equity | SEK 4,3M | +28% |
| Employees | 1 | — |
Legal name
Novadoc AB
Org number
5590754031
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
7 september 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av ledamoten
Company purpose
Föremålet för bolagets verksamhet är läkarverksamhet, utbildningsverksamhet inom IT, konst, och språk samt bedriva handel med värdepapper, äga och förvalta handel med ädelmetaller och därmed förenlig verksamhet.
Address
Toftavägen 25
Email
nic_s_nic@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 004 | 1 886 | 1 923 | 2 202 | 1 896 |
| Staff expenses | — | −1 468 | −1 248 | −1 164 | −348 |
| EBITDA | 348 | 338 | 582 | 884 | 1 492 |
| Depreciation & amort. | −0 | — | 6 | — | −9 |
| EBIT | 348 | 338 | 588 | 884 | 1 483 |
| Net financials | 195 | 19 | 55 | 331 | −27 |
| Profit before tax | 684 | 647 | 479 | 1 537 | 1 752 |
| Tax | −144 | −142 | −102 | −326 | −369 |
| Net profit | 540 | 505 | 376 | 1 211 | 1 383 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 527 | 4 259 | 4 177 | 4 631 | 5 256 |
| Equity | 2 923 | 2 864 | 2 681 | 3 327 | 4 266 |
| Long-term debt | 0 | — | — | — | — |
| Short-term debt | 271 | 352 | 289 | 418 | 400 |
| Total debt | 271 | 352 | 289 | 418 | 400 |
EBITDA margin
78.7%
This company
15.8%
Market median
+398% vs market
20212025
Equity ratio
81.2%
This company
38.2%
Market median
+113% vs market
20212025
Return on equity
32.4%
This company
18.4%
Market median
+76% vs market
20212025
Net profit margin
72.9%
This company
8.1%
Market median
+800% vs market
20212025
Asset turnover
0.36×
This company
1.12×
Market median
-68% vs market
20212025
Debt / equity
0.23×
This company
0.62×
Market median
+63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
HG | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2024 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2024 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Novadoc AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hans Georg Bo Ehrlinder | Audit | 0 companies |
| Liliya Nicolaidis | Deputy Board Member | 0 companies |
| Stylianos-Nicholas Nicolaidis | Board of Directors | 0 companies |
| Marie Ann-Sofi Löfgren | Deputy Board Member | 0 companies |